Study of ManNAc for kidney diseases with proteinuria
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called ManNAc for people with certain kidney diseases (FSGS, MCD, or MN) that cause protein in the urine. The goal is to see if this drug can help reduce protein loss and improve kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney biopsy showing one of these conditions: FSGS, MCD, or MN, within the last 10 years.
- Your urine protein level must be high (at least 2 grams per gram of creatinine) on three separate tests.
- Your kidney function must be at a certain level (eGFR of at least 30).
- You must be at least 18 years old and weigh more than 50 kg (about 110 pounds).
- You must be willing to use effective birth control (if applicable) and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This study compares two experimental treatments—one that reduces protein in urine and another that may help control blood sugar and weight—for people with chronic kidney disease. It aims to find safer, more effective ways to slow kidney damage.
This trial tests a medicine called atacicept in adults and children with several types of kidney disease. The goal is to see if it can reduce protein in the urine and help protect kidney function.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
Hear when a new Focal Segmental Glomerulosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.